Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses of any major malignancy and exhibits profound chemoresistance (1) (2) (3) . the inefficacy of currently available therapeutic strategies has been attributed to the dense desmoplastic reaction, which reduces drug penetration, and to the high rate of genetic alterations affecting multiple pathways (4, 5) . Genetic analyses uncovered mechanisms controlling pancreatic carcinogenesis (6) and studies to identify aberrancies associated with outcome are warranted.
We previously investigated genomic imbalances using arraycomparative genomic hybridization in a cohort of 44 radically resected patients, the largest PDAC series ever investigated by array-comparative genomic hybridization (7) . In this series, the median overall survivals (oS) for patients with and without loss of the cytoband 18q22.3 were 7.6 and 21.4 months, respectively (P = .02, two-sided log-rank test). the cytoband 18q22.3 contains five known genes (FBXO15, c18orf55, CYB5A, c18orf51, and CPGL). In agreement with previous findings (8) , CPGL reduced proliferation and inhibited migration in Su.86.86 cells carrying FLAG-tagged CPGL. however, knockdown of CPGL in the PANC-1 cells did not affect proliferation, cell cycle distribution, and wound healing (7) . the aim of this study was to evaluate whether the mrNAs and/or proteins coded by the genes in the 18q22.3 cytoband were associated with outcome in two cohorts of radically resected patients and one cohort of metastatic PDAC patients. Further, we aimed to characterize key factors affecting proliferative and invasive capacity, as well as autophagy induction, which may provide mechanistic insights on PDAC aggressive behavior and contribute to the rational development of new prognostic and therapeutic approaches.
Methods

Cell Lines
AsPc1, BxPc-3, Capan-2, CFPAC-1, hPAC, mIA PaCa-2, PANC-1, PL45, Su.86.86, SuIt2-007, SuIt2-028, and htert-hPNe were from American type Culture Collection (manassas, VA). Five primary cultures (PDAC-1/-2/-3/-4/-5) were isolated at Pisa university hospital (9) .
Patient Samples the primary tumors (n = 130) of the two cohorts of PDAC patients were resected with pancreatico-duodenectomy or total/distal-pancreatectomy before adjuvant treatment, which consisted of gemcitabine-based combined modality (eg, gemcitabine 1000 mg/m 2 /day on days 1, 8, and 15 every 28 days, followed by gemcitabine 300 mg/ m 2 weekly plus concomitant radiation therapy to a total of 45 Gray). Clinicopathological characteristics of these patients are reported in Supplementary table 1, A and B (available online).
Fresh-frozen samples from the first cohort (n = 48, stage IIb, pt3N1mx according to American Joint Committee on Cancertumor Node metastasis staging system), which were collected from December 2001 to october 2004, were stored until laser microdissection. Similarly, 33 biopsies from metastatic tumors were collected before treatment (gemcitabine 1000 mg/m 2 /day on days 1, 8, and 15). Patients were followed-up for 1.6 to 56.5 months (median = 18.2 months) until January 2010.
Patients were stratified according to the median expression of target genes. Disease-free survival was defined as the time from the diagnosis to the first relapse or last follow-up in radically resected patients. Progression-free survival was defined as the time from the diagnosis to the first progression or last follow-up in metastatic patients. oS was calculated from the diagnosis to the death or last follow-up.
tissue microarrays (tmAs) were constructed using core tissue biopsies from formalin-fixed paraffin-embedded specimens of the second cohort (n = 82). two additional tmAs were constructed with 50 samples from metastatic patients.
All specimens were obtained after patient's written consent approved by the Pisa university hospital ethics Committee. Detailed methods for laser microdissection and construction of tmAs can be found in the Supplementary methods (available online).
Quantitative Reverse-Transcription Polymerase Chain Reaction and Immunohistochemistry expression of FBXO15, C18orf55, CYB5A, CPGL, and CPGL-B was evaluated in 48 patients undergoing surgical resection and 33 metastatic patients (7, 9) , whereas CyB5A protein expression was evaluated in tmAs from a second cohort (n = 82) of radically resected (10) patients and 50 metastatic patients, as described in the Supplementary methods (available online).
In Vitro Studies
PDAC-2 and Su.86.86 cells were transduced with PLNCX2/ CyB5A-yFP constructs (Supplementary Figure 1, A and B, available online), or transfected with 25 nmol/L CYB5A small interfering rNA or negative control (s223365 and Silencer Negative Control #1; Ambion, Foster City, CA). CYB5A expression was compared with htert-hPNe using the 2 -ΔΔCt method.
ultrastructural analysis and CyB5A and LC-3 immunoblotting/fluorescence were performed as previously described (9, 11) .
Autophagy-related genes were assessed using the Autophagyrt2-Profiler PCr-Array (Qiagen, hilden, Germany). Kinase activity was evaluated by peptide substrate array (PamGene, 's-hertogenbosch, the Netherlands), as described (12) .
Functional and physical interactions of CyB5A were retrieved using StrING (13) . Data were loaded in Cytoscape version 2.8.3, and networks were merged with embedded analysis tools. Clustering of the final network was obtained with Clusterone plug-in version 1.1, whereas the BINGo plug-in provided ontologies for each cluster (14, 15) .
Further details on proliferation, migration, invasion, immunoblotting, DNA damage, apoptosis, and autophagy assays are in the Supplementary methods (available online).
In Vivo Studies PDAC-2 cells were transduced with lentiviral vectors containing Firefly luciferase (Fluc)/mCherry, and Gaussia luciferase(Gluc)/ CFP, as described (16, 17) . Cells were then transduced with PLNCX2/CyB5A-yFP or control constructs and injected in the pancreas of 12 randomized mice: six PLNCX2/CyB5A-yFP (CyB5A+) and six PLNCX2/yFP (Ctr group). tumor growth was monitored by charge-coupled device camera imaging. experiments were carried out according to a protocol approved by the Vu university Amsterdam, the Netherlands. Further details are in the Supplementary methods (available online).
Statistical Analyses
All experiments were performed in triplicate and repeated three times. Data were expressed as mean values ± standard errors and analyzed by Student t test or mann-Whitney test followed by the tukey multiple comparison. Associations between clinicopathologic features were tested by Fisher exact test. Kaplan-meier and log-rank methods were used to compare disease-free survival/progressionfree survival and oS curves using SPSS version 20 (IBm, Chicago, IL). Statistically significant variables in the univariable analysis were included in multivariable analysis using Cox proportional hazards model. the proportional hazards assumption was satisfied using the Schoenfeld residuals method. All statistical tests were two-sided. A P value of less than .05 was considered statistically significant. Figure 1A depicts FBXO15, c18orf55, CYB5A, CPGL, and CPGL-B transcripts variation according to CPGL deletion, which is used as an indicator of cytoband 18q22.3 deletion (7). median expression values of CYB5A and c18orf55 were statistically significantly lower in deleted samples (P < .05, two-sided mann-Whitney test). CPGL deletion was confirmed to have prognostic value (table 1), as well as grading. however, considering the five genes studied, only patients with CYB5A expression below median had a statistically significantly shorter oS (median oS = 16.3, 95% confidence interval [CI] = 13.4 to 19.1; vs median oS = 29.5 months, 95% CI = 11.1 to 47.8; hazard ratio [hr] = 2.3, 95% CI = 1.2 to 6.0; P = .01, two-sided log-rank test) ( Figure 1B) . Similar results were . P values were calculated with two-sided Mann-Whitney test. C18orf51 was not included because it was not detectable in preliminary analyses in PDAC cells. B) Survival curves according to polymerase chain reaction data of CYB5A mRNA expression in the patients from the first cohort, grouped according to high/low vs median values. P values were calculated with two-sided log-rank test. C) Survival curves according to CYB5A protein expression in the 82 radically resected PDAC patients of the second cohort (high/low staining score values, as explained in the Supplementary Methods, available online). All patients received the same gemcitabine-based adjuvant chemotherapy, but 13 patients in this cohort had stage IIA PDACs (pT3N0Mx), and fewer tumors exhibited grade 3 histological differentiation in comparison with those in the first cohort (Supplementary Table 1 , available online). P values were calculated with two-sided log-rank test. D and E) Survival curves according to CYB5A mRNA and protein expression in the metastatic patients (mRNA expression data were available for 33 patients, whereas protein expression data were available for 50 patients). P values were calculated with two-sided log-rank test. The number of patients at risk in each group is given in the tables below the graphs.
results
CYB5A mRNA and Protein Expression and Outcome
observed for disease-free survival (table 1), whereas there was no difference in CYB5A levels according to grade (Supplementary  table 1C, available online) .
the prognostic role of CyB5A was confirmed in an independent cohort of radically resected patients (table 2), in whom protein expression was evaluated by immunohistochemistry (Supplementary Figure 2 , available online). Patients with low CyB5A expression had median oS of 16.7 months (95% CI = 13.5 to 19.9), whereas remaining patients had median oS of 24.8 months (95% CI = 12.8 to 36.9; hr = 1.9, 95% CI = 1.2 to 3.6; P = .02, twosided log-rank test) ( Figure 1C ). CyB5A was also associated with disease-free survival (table 1), whereas there were no differences in Figure 1 , C and D). No differences were observed in analysis by sex (data not shown).
Effects of CYB5A on Cell Growth and Invasion to study the biological role of CYB5A, we initially assessed its mrNA expression, demonstrating lower expression levels in all malignant cells compared with nontumorigenic cells (Figure 2A) . remarkably, CYB5A levels in primary cultures were correlated (R 2 = 0.901; P = .01, two-sided Spearman test) to the values detected in their tissues of origin, suggesting that these cultures are reliable models.
Su.86.86 and PDAC-2 cells were selected for further investigation because they carried the 18q22.3 cytoband loss (Supplementary Figure 3 , available online) and expressed the lowest levels of CYB5A mrNA. We successfully established CyB5A-overexpressing subclones and empty vectors with more than 90% efficiency in each cell type (Supplementary Figure 4 , A and B, available online). Furthermore, quantitative reverse-transcription polymerase chain reaction demonstrated a 7-fold and 20-fold increase of CYB5A expression in Su.86.86-CyB5A+ and PDAC-2-CyB5A+, respectively (Figure 2A ). these CyB5A+ subclones showed slower proliferation rates, as well as less wound healing (Figure 2 , B and C) and invasion (Supplementary Figure 4C , available online), indicating that CyB5A expression leads to both growth inhibition and attenuated cell migration. CyB5A small interfering rNA transfection of PDAC-2-CyB5A+ subclones restored proliferation (data not shown) and wound healing Figure 4D , available online). Conversely, no differences were detected for double-strand breaks (Supplementary Figure 5 , available online).
Effects of CYB5A on Autophagy
Annexin-V staining showed a statistically significant increase in apoptosis in both Su86.86-CyB5A+ (P = .02, two-sided t test) and PDAC-2-CyB5A+ (P = .02, two-sided t test), as shown in Figure 2D . In Su.86.86-CyB5A+, early apoptosis was increased from 2.3% to 9.1%, whereas late-apoptosis was increased from 4.5% to 9.5%. A similar increase was also observed for mitochondrial damage (Supplementary Figure 6A , available online), with a clear decrease of DioC6 binding in CyB5A+ cells (P = .02, twosided t test). however, the most striking effect of CYB5A transduction was the different morphological appearance of CyB5A+ cells, which showed a round shape and a dramatic increase in cytoplasmic vacuolization. Cytoplasm and nucleoplasm were slightly darker, and ultrastructural analysis revealed double-membrane vesicles containing engulfed cytoplasmic contents and autophagolysosomes (Figure 2e ). Quantitative analysis confirmed increased autophagic vacuoles formation and accumulation of residual bodies and autophagolysosomes (+25% and +33% vs. Ctr, respectively); this was further induced by chloroquine, (+35% and +41% vs. Ctr, respectively), which was also able to inhibit cell proliferation (Supplementary Figure 6B, available online) . the ability of CyB5A to induce autophagy was supported by the increase of acridine-orange-stained cells, double-labeling of CyB5A and LC3-II, and immunoblotting (Supplementary Figure 6 , C-e, available online).
Effects of CYB5A on Proautophagic Pathways and Oncogenic Kinases
to shed light on the molecular events driving autophagy, we evaluated 84 genes encoding key components of the autophagic machinery. the volcano plot in Figure 3A arranged the genes along differential regulation (up-or downregulation, x-axis) and statistical significance (y-axis) of genes in CyB5A+ compared with Ctr cells. Sorting for threefold change cutoff, this analysis identified 11 relevantly upregulated genes, including the ATG genes ATG5, ATG7, ATG9A, and ATG16L2, the ATG8 homolog MAPLC3A, the proautophagic gene AMBRA1, and the coregulators of autophagy and apoptosis BAX and DRAM1 (18) . however, we also observed a marked increase of HSP90AA1; NFKB1, which is frequently overexpressed in PDAC (19) ; and CXCR4, which has been linked to PDAC metastasis (20) . the downregulated genes included the major antiapoptotic players BCL-2 and AKT1, as well as RPS6KB1, which repress BAD proapoptotic function (21) . Another striking finding was the downregulation of MAPK14, which is one of the four p38-mAPKs involved in cascades of cellular responses evoked by proinflammatory cytokines or physical stress.
Based on these results, we initially built two separate networks; the first was composed of all possible interactions for CyB5A, whereas the second included interactions retrieved for the genes that had differential expression on the polymerase chain reaction array ( Figure 3B ). these analyses revealed that the physical interaction of CyB5A with trAF6 (22) constitutes a molecular bridge for many signals, both upstream and downstream, including Akt and mAP-kinases, as well as for genes involved in cell death. * CI = confidence interval; df = degrees of freedom; HR = hazard ratio; OS = overall survival; PFS = progression-free survival; WHO = World Health Organization. † Calculated using log-rank two-sided test. ‡ Calculated using Cox's proportional hazards two-sided test.
CyB5A+ cells had a statistically significant reduction of trAF6 levels (−54% and −69% vs Ctr, two-sided t-test P = .02, and P = .005 in PDAC-2 and Su.86.86 cells, respectively), which was restored in rescue experiments with CyB5A small interfering rNA ( Figure 3C) . moreover, we observed a reduction of the phosphorylation of mAPK14 peptide substrate, consistent with statistically significant reduction of phospho-mAPK14 (P < .01, two-sided t test) ( Figure 3D-e) , as well as a marked reduction of Src and eGFr substrates phosphorylation (in y908/y1062/y962). Figure 4A shows Fluc signal in mice injected with PDAC-2-Fluc/mCherry cells, indicating tumor engraftment and growth. this signal was statistically significantly lower in CyB5A+ mice (1.7 × 10 10 vs 4.6 × 10 10 photons/sec/cm 2 at day 35; P = .006, twosided t test). magnetic resonance imaging confirmed the localization of tumor cells in the mouse pancreas, as well as retroperitoneal invasion, whereas high-frequency ultrasound enabled the assessment of vasculature networks (Supplementary Figure 7, A and B, and video, available online). Gluc signal further supported the reduced tumor burden due to CYB5A transduction (3.8 × 10 4 vs 6.9 × 10 4 relative light units/seconds at day-35; P = .01, two-sided t test) ( Figure 4B ).
Effects of CYB5A In Vivo
Fluorescence microscopy identified yFP-marked CyB5A+ cells in pancreatic cross-sections (data not shown). the differential expression of CyB5A was confirmed by immunohistochemistry, which also detected its variability in three other models of orthotopic PDACs (Supplementary Figure 7C, available online) .
Survival analysis demonstrated that mice of the CyB5A+ group lived longer (median oS = 57 days, 95% CI = 52 to 61; vs. median oS = 44 days, 95% CI = 21 to 57; P = .03, two-sided log-rank test; hr = 0.4, 95% CI = 0.1 to 0.8) (Figure 4C ). Numerous macroscopic metastases were observed in all of the livers of Ctr mice (Figure 4 , D and e), whereas no liver metastases were detected in 33% of CyB5A+ mice.
remarkably, PDACs in the CyB5A+ group demonstrated reduced expression of trAF6 associated with increased expression of its turnover regulator p62 (23) and of the autophagic markers LC3-II, AtG7, and AtG16L2 ( Figure 5, A-C) . 
Discussion
our results support a role for CyB5A as a novel prognostic factor in PDAC and unravel its inhibitory activity of oncogenic phenotypes through modulation of autophagic, apoptotic, and invasive processes.
Because the high rates of genetic alterations and chromosomal instability in core signaling pathways are a major cause for the intrinsic aggressiveness of PDAC (6, 24) , we recently performed a genome-wide screening supporting the prognostic role of the cytoband 18q22.3 (7) . In this study we further explored the clinical relevance of this discovery and reported the key role of CyB5A in both radically resected and metastatic PDAC patients.
In agreement with previous data (25), our multivariable analyses showed the association of grading to patient outcome. however, in a validated PDAC nomogram, pathologic features contribute less than 10% to survival predictions (26) , and identification of new prognostic factors appears to be critical to improve the clinical management of PDAC (27) . moreover, prognostic biomarkers provide mechanistic insights into cancer progression and might identify novel molecular targets (28) .
Bench-to-bedside research on hundreds of samples improved prognostic capabilities in several tumor types, such as breast cancer (29) . Similar studies are difficult in PDACs, which are characterized by high nuclease activity and small amount of tissue. most candidate biomarkers are based solely on mrNA evidence from tissues that were not microdissected to separate cancer stroma (30) . molecules with both mrNA and protein evidence in independent cohorts of patients are high-priority candidates, and our findings on CyB5A prompt prospective studies for further validation.
microarray analyses revealed CYB5A downregulation compared with paired and unpaired normal pancreatic tissues (31) (32) (33) (34) , which is in agreement with the lower expression levels of CYB5A in all of our PDAC cells compared with normal cells. moreover, a recent study identified CYB5A among genes that had lower copy number in lung squamous cell carcinomas of patients who had recurrence (35) , but it is unclear which exact mechanism is responsible for the difference in clinical outcome.
CyB5A is a membrane-bound cytochrome that reduces methemoglobin to ferrous haemoglobin, and defects in this gene cause type IV methemoglobinemia (36) . Additionally, it functions as an electron carrier for several oxygenases and plays a key role in the reductive detoxification of arylhydroxylamines (37) .
here for the first time we compared the behaviour of gainand loss-of-function models of PDAC. In these models, CyB5A upregulation suppressed proliferation and migration/invasion, which were restored by silencing. moreover, mice with CyB5A+ retrovirus-transduced PDACs had statistically significant increased survival and decreased tumor dimension and metastatic spread.
Studies on molecular basis of these reduced proliferation and invasive/metastatic abilities showed a statistically significant increase in both early and late apoptosis, accompanied by marked accumulation of autophagic vacuoles. the role of autophagy in PDAC remains to be elucidated (38) . Several studies suggest that autophagy promotes tumorigenesis and protects cancers (39, 40) . other lines of investigation showed that autophagy is detrimental to tumor cells, demonstrating the induction of VmP1-mediated autophagy in response to gemcitabine in PANC-1 and mIA PaCa-2 cells (41) . Similarly, sulforaphane caused both autophagy and apoptosis in several PDAC-derived cells (42) .
In our in vitro and in vivo models, activation of proautophagic/ apoptotic pathways was coupled with a statistically significant upregulation of several ATG genes. Interestingly, we also observed a downregulation in expression and phosphorylation of mAPK14. Networks analysis and modulation of trAF6 in cells and tumors Figure 4 . Effects of CYB5A in vivo. A) Five days after injection, primary tumors were detectable in all mice (ie, 100% take rate, without surgeryrelated mortality), and Fluc activity (proportional to the number of cancer cells, carrying Fluc/mCherry) increased over time. B) BLI signal of the pancreatic ductal adenocarcinoma patients (PDAC) tumors as detected in the blood samples with the Gluc (proportional to the number of cancer cells, carrying Gluc/CFP). P values were calculated with two-sided Student t test. C) Survival curves in the two groups of mice. Statistically significant differences were determined by two-sided log-rank test.
The number of mice at risk in each group is given below the graph. D) Number of liver metastases in the two groups of mice. All mice were also evaluated for the presence of metastatic localization in other organs, and lung metastases were identified in two of six animals of the control (CTR) group. P values were calculated with two-sided Student t test. E) Immunofluorescence image of a representative section showing a liver metastasis in a mouse from the CYB5A+ group (YFP-positive cells). Points or columns indicate mean values obtained from the analysis of the six mice in each group. Bars indicate standard deviation. *P < .05.
with CYB5A transduction (or silencing) suggested its pivotal role in CyB5A multipathway regulation. trAF6 is a member of the trAF family with unique binding activities that result in signaling responses from interleukin 1 receptor (IL-1r), toll-like receptor (tLr), CD40, and rANK (43) . trAF6 associates directly with CD40 and rANK and indirectly with IL-1r/tLr through IrAK1 and IrAK2. this leads to activation of mAP-kinase signaling through downstream association with tGF-beta activating kinase 1 (tAK1)-binding protein complex (44) . Additionally, trAF6 modulates Src kinases leading to Akt activation (45) . this cross-talk might explain our data on apoptosis induction and inhibition of tumor invasion/metastasis, in agreement with previous results in PDAC cells and orthotopic models (46) . of note, Src family members are commonly activated by growth factors such as eGF, with the formation of a complex where Src phosphorylates the associated receptor enhancing its activity (47) . this could determine the downregulation of Src and eGFr, which are associated with reduced proliferation in our CyB5A+ models.
Limitations of this study include the fact that CyB5A was tested retrospectively in PDAC tissues and on a small number of primary cells. Further studies in prospective series and additional models are needed. however, our findings raise also the possibility that strategies aimed at restoring CyB5A activity, through gene therapy that replaces the function of this gene or targeted therapy inhibiting its deregulated downstream trAF6, may constitute a novel strategy that favors cancer cell death while preventing potentially deleterious cross-talk between eGFr, Akt, and Src pathways in specific subgroups of PDAC patients. on the front of cancer therapeutics, trAF6 has been implicated as an oncogene in lung cancer and as a target in multiple myeloma (48, 49) . trAF2, which shares many functional similarities with trAF6, is overexpressed in pancreatic tumors and cells, promotes invasiveness, and protects from CD95-mediated apoptosis (50) . Furthermore, silencing or inhibition of tAK1 emerged as a potential approach to counteract antiapoptotic signaling pathways and PDAC chemoresistance (19) . Future studies on inhibitors of trAF6, such as cell-permeable trAF6 decoy peptides that can target the trAF6/binding peptide interaction (43) , are warranted.
In conclusion, our clinical data, together with our in vitro and in vivo findings, strongly suggest that PDACs are more aggressive if they have low expression of CyB5A and deregulation of its downstream pathways, which therefore represent promising new tools for prognostic and therapeutic purposes. 
